PNAA
TEVA icon

Pictet North America Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Pictet North America Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,864
Closed -$300K – 131
2023
Q1 		$300K Sell
33,864
-45,825
-58% -$453K 0.05% 109
2022
Q4 		$727K Sell
79,689
-845,718
-91% -$7.38M 0.13% 83
2022
Q3 		$7.47M Sell
925,407
-5,825
-0.6% -$51.5K 1.19% 26
2022
Q2 		$7M Sell
931,232
-33,678
-3% -$293K 0.93% 29
2022
Q1 		$9.06M Sell
964,910
-8,218
-0.8% -$68.6K 1.05% 27
2021
Q4 		$7.79M Sell
973,128
-7,077
-0.7% -$63.9K 0.77% 31
2021
Q3 		$9.55M Sell
980,205
-6,957
-0.7% -$65.1K 0.94% 30
2021
Q2 		$9.83M Buy
987,162
+12,693
+1% +$134K 1.02% 27
2021
Q1 		$11.1M Buy
974,469
+875,006
+880% +$10M 1.3% 25
2020
Q4 		$946K Buy
99,463
+39,768
+67% +$381K 0.12% 78
2020
Q3 		$541K Sell
59,695
-6,750
-10% -$71.4K 0.08% 98
2020
Q2 		$800K Hold
66,445
– – 0.11% 85
2020
Q1 		$612K Buy
+66,445
New +$681K 0.1% 93
2019
Q2 		– Sell
-60,994
Closed -$950K – 157
2019
Q1 		$950K Sell
60,994
-2,651
-4% -$46.8K 0.14% 83
2018
Q4 		$999K Sell
63,645
-46,232
-42% -$948K 0.09% 77
2018
Q3 		$2.41M Buy
109,877
+4,049
+4% +$94K 0.32% 50
2018
Q2 		$2.51M Buy
105,828
+12,338
+13% +$252K 0.37% 48
2018
Q1 		$1.59M Buy
+93,490
New +$1.83M 0.24% 63
2017
Q4 		– Sell
-105,149
Closed -$1.84M – 137
2017
Q3 		$1.84M Buy
+105,149
New +$2.37M 0.29% 60
2017
Q2 		– Sell
-471,083
Closed -$15.5M – 138
2017
Q1 		$15.5M Buy
+471,083
New +$16.1M 2.58% 14

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet North America Advisors's TEVA Position: Q2 2023 in Review

Pictet North America Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 33,864 shares — an estimated $300K sold.

Pictet North America Advisors first reported a position in TEVA in Q1 2017 and held it in 20 quarters. The position peaked at $15.5M in Q1 2017. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Pictet North America Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Pictet North America Advisors sold 33,864 Teva Pharmaceuticals shares in Q2 2023, an estimated $300K.
  • Pictet North America Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 20 quarters.
  • Pictet North America Advisors's Teva Pharmaceuticals position peaked at $15.5M in Q1 2017.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Pictet North America Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.